Chronic lymphocytic leukemia in a Japanese population: Varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behavior

Leukemia and Lymphoma

Volumn 51, Issue 12, 2010, Pages 2230-2239

  Tomomatsu, Junichi ^a   Isobe, Yasushi ^a   Oshimi, Kazuo ^a   Tabe, Yoko ^a   Ishii, Kiyoshi ^b   Noguchi, Masaaki ^c   Hirano, Takao ^d   Komatsu, Norio ^a   Sugimoto, Koichi ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY HOSPITAL   (Japan)

^c JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^d JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

Author keywords

Chronic lymphocytic leukemia; immunophenotype; thymidine kinase activity; VH usage

Indexed keywords

CD20 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; THYMIDINE KINASE; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; CANCER CLASSIFICATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE MUTATION; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOPHENOTYPING; JAPANESE; MALE; MORPHOLOGY; PLASMACYTOMA; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENES, BCL-2; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; ONCOGENE PROTEINS, FUSION; POPULATION; PROGNOSIS;

EID: 78650059533     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.527403     Document Type: Article

References (37)

1. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute Working Group 1996 guidelines. Blood 2008;111:5446-5456.
2. Mü ller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. pp 180-182.
3. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8: 1640-1645.
4. Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 2007;139:809-819.
5. Tamura K, Sawada H, Izumi Y, et al. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. Eur J Haematol 2001;67:152-157.
6. Gale RP, Cozen W, Goodman MT, Wang FF, Bernstein L. Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County. Leuk Res 2000;24:665-669.
7. Damle RN, Wasil T, Fais F, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.
8. Krö ber A, Seiler T, Benner A, et al. VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-1416.
9. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775. (Pubitemid 36514707)
10. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901.
11. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105-111.
12. Duke VM, Gandini D, Sherrington PD, et al. VH gene usage differs in germline and mutated B-cell chronic lymphocytic leukemia. Haematologica 2003;88:1259-1271.
13. Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004;104:2879-2885.
14. Koiso H, Yamane A, Mitsui T, et al. Distinctive immunoglobulin VH gene usage in Japanese patients with chronic lymphocytic leukemia. Leuk Res 2006;30:272-276.
15. Chen L, Zhang Y, Zheng W, et al. Distinctive IgVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia. Leuk Res 2008;32:1491-1498.
16. Aoki R, Karube K, Sugita Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006. Pathol Int 2008;58:174-182.
17. Rawstron AC, Bennett FL, OConnor SJM, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008;359:575-583.
18. Del Principe MI, Del Poeta G, Buccisano F, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006;108:853-861.
19. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102:1515-1525.
20. Garand R, Sahota SS, Avet-Loiseau H, et al. IgG-secreting lymphoplasmacytoid leukemia: a B-cell disorder with extensively mutated VH genes undergoing Ig isotype-switching frequently associated with trisomy 12. Br J Haematol 2000; 109:71-80.
21. Guarini A, Gaidano G, Mauro FR, et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotype and genotypic features. Blood 2003;102:1035-1041.
22. Oscier D, Fegan C, Hillmen P, et al., Guidelines Working Group of the UK CLL Forum. British Committee for Standards in Haemotology. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004;125:294-317.
23. Wierda WG, OBrien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007;109:4679-4685.
24. Deaglio S, Vaisitti T, Aydin S, Ferrero E, Malavasi F. Intandem insight from basic science combined with clinical research: CD38 as both marker and key component of pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006;108:1135-1144.
25. Zenz T, Mertens D, Kü ppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37-50.
26. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003;101:1087-1093.
27. Hashimoto S, Dono M, Wakai M, et al. Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgGCD5 chronic lymphocytic leukemia B cells. J Exp Med 1995;181:1507-1517.
28. Potter KN, Mockridge I, Neville L, et al. Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia. Clin Cancer Res 2006;12: 1672-1679.
29. Scielzo C, Camporeale A, Geuna M, et al. ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturation stage. Leukemia 2005;20:689-695.
30. OBrien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-2170. (Pubitemid 32366970)
31. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-2164.
32. Thorsé lius M, Walsh S, Eriksson I, et al. Somatic hypermutation and VH gene usage in mantle cell lymphoma. Eur J Haematol 2002;68:217-224.
33. Camacho FI, Algara P, Rodriguez A, et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood 2003;101: 4042-4046.
34. Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999;17:2454-2460.
35. Tsimberidou A-M, Wen S, McLaughlin P, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 2008;27:904-910.
36. Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999;93:1732-1737.
37. Matthews C, Catherwood MA,Morris TCM, et al. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression. Eur J Haematol 2006;77:309-317.